乳腺癌新辅助化疗及预后的相关研究  

The study of neoadjuvant chemotherapy and prognosis of breast cancer

作　　者：林志琴 曾澄 冯远平 彭涛 赖闺娥[2] 刘凤恩[2] LIN Zhi-qin;ZENG Cheng;FENG Yuan-ping;PENG Tao;LAI Gui-er;LIU Feng-en(Gannan Medical University;Department of Vascular and Breast,The First Affiliated Hospital of Gannan Medical University,Ganzhou,Jiangxi 341000)

机构地区：[1]赣南医学院 [2]赣南医学院第一附属医院血管乳腺外科,江西赣州341000

出　　处：《赣南医学院学报》2022年第3期265-269,共5页JOURNAL OF GANNAN MEDICAL UNIVERSITY

摘　　要：乳腺癌不是乳房单纯的病变,而是全身性病变,单靠手术切除乳房肿瘤或切除乳房很难达到根治性效果,容易引起复发或远处转移。乳腺癌化疗分为术前化疗及术后化疗,术前化疗又称为新辅助化疗。新辅助化疗的出现,不仅提高了手术切除率,降低分期,提高保乳手术率,且普遍认为新辅助化疗后达到病理完全缓解(Pathological complete remission,pCR)的患者生存期可有很大改善。但影响新辅助化疗疗效的因素很多,本文就新辅助化疗及预后的相关研究进行综述。Breast cancer is not a simple lesion of the breast,but a systemic lesion.It is difficult to achieve a radical ef⁃fect by surgical resection of breast tumor or breast resection alone,and it is easy to cause recurrence or distant metasta⁃sis.Breast cancer chemotherapy is divided into preoperative chemotherapy and postoperative chemotherapy.Preopera⁃tive chemotherapy is also known as neoadjuvant chemotherapy.The emergence of neoadjuvant chemotherapy not only im⁃proves surgical resection rate,reduces staging,and improves breast-conserving surgery rate,but also it is generally be⁃lieved that the survival of patients who achieve pathological complete response(pCR)after neoadjuvant chemotherapy can be greatly improved.However,there are many factors that affect the efficacy of neoadjuvant chemotherapy.In this paper,relevant studies on neoadjuvant chemotherapy and prognosis are summarized.

关 键 词：新辅助化疗 病理完全缓解 无进展生存期 总生存期 

分 类 号：R658.3[医药卫生—外科学]